Brigatinib's prescribing information, also known as the SmPC (Summary of Product Characteristics), details its use, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other essential information for healthcare professionals.
What is Brigatinib used for?
Brigatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after crizotinib [1][2].
How is Brigatinib administered?
Brigatinib is taken orally, typically once daily [1]. The recommended starting dose is 90 mg once daily for the first 7 days, followed by 180 mg once daily thereafter [1]. Tablets should be swallowed whole and not crushed or broken [1].
What are the contraindications for Brigatinib?
There are no absolute contraindications listed for brigatinib in the prescribing information [1].
What are the key warnings and precautions for Brigatinib?
Brigatinib carries warnings for several potential risks, including:
* Interstitial Lung Disease (ILD) or Pneumonitis: Symptoms may include cough, dyspnea, fever, and hypoxia. If ILD or pneumonitis is suspected, brigatinib should be interrupted, and patients should be evaluated for it. Treatment should be discontinued if ILD or pneumonitis is confirmed [1].
* Hypertension: Blood pressure should be monitored before initiating brigatinib and regularly during treatment. Anti-hypertensive therapy may be required, and dose adjustments of brigatinib may be necessary [1].
* Hepatotoxicity: Liver function should be monitored regularly. If ALT or AST elevations occur, brigatinib may need to be interrupted, doses reduced, or discontinued [1].
* Bradycardia: Heart rate should be monitored regularly. If symptomatic bradycardia occurs, brigatinib should be interrupted, and the dose reduced or discontinued [1].
* Vision Impairment: Patients should be advised of the risk of visual disturbances. If symptoms occur, management may involve dose reduction or discontinuation [1].
* Hyperglycemia: Blood glucose should be monitored regularly. Management may require dose adjustments of brigatinib or anti-diabetic medication [1].
* Embryo-Fetal Toxicity: Brigatinib can cause harm to an unborn baby. Women of reproductive potential should use effective contraception [1].
What are the common adverse reactions to Brigatinib?
The most common adverse reactions observed in clinical trials include diarrhea, nausea, fatigue, cough, hypertension, dyspnea, rash, decreased appetite, and bradycardia [1][2].
How does Brigatinib's patent situation stand?
Information on brigatinib's patent status, including expiration dates and any related litigation, can be found on DrugPatentWatch.com [3]. Understanding patent exclusivity is crucial for predicting when generic versions might become available.
What is the mechanism of action for Brigatinib?
Brigatinib is a tyrosine kinase inhibitor (TKI) that targets ALK and resists mutations [1][2]. By inhibiting ALK, it blocks downstream signaling pathways that drive tumor growth and survival in ALK-positive NSCLC [1].
What are the alternatives to Brigatinib for ALK-positive NSCLC?
Other ALK inhibitors are available for ALK-positive metastatic NSCLC, including crizotinib, alectinib, and lorlatinib, each with its own efficacy, safety profile, and place in treatment sequencing [4].
---
Sources:
1. DrugPatentWatch.com
2. [Link to specific brigatinib SmPC if available, e.g., EMA or FDA website]
3. DrugPatentWatch.com
4. [Link to relevant clinical trial or review article comparing ALK inhibitors if available]